Syndax Pharmaceuticals, Inc.
SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.39
Price-3.26%
-$0.72
1Y
Price
Market Cap
$1.851b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-125.8%
EBITDA Margin-132.4%
Net Profit Margin-154.0%
Free Cash Flow Margin-125.8%
EBITDA Margin-132.4%
Net Profit Margin-154.0%
Free Cash Flow MarginRevenue
$111.551m
+371.1%
1y CAGR+123.7%
3y CAGR+67.8%
5y CAGREarnings
-$311.577m
+2.3%
1y CAGR-30.1%
3y CAGR-197.3%
5y CAGREPS
-$3.62
+3.0%
1y CAGR-14.4%
3y CAGR-164.0%
5y CAGRBook Value
$115.430m
$551.792m
Assets$436.362m
Liabilities$345.431m
DebtDebt to Assets
62.6%
-1.2x
Debt to EBITDAFree Cash Flow
-$311.011m
-13.1%
1y CAGR-34.7%
3y CAGR-166.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company